Rajat Bannerji, MD, PhD | Authors


Anti-CD20 Agent Yields High Responses in Follicular Lymphoma

January 22, 2020

Rajat Bannerji, MD, PhD, discusses the safety and efficacy results of REGN1979 in the follicular lymphoma cohort enrolled in the phase I study of patients with relapsed/refractory B-Cell non-Hodgkin lymphoma who were previously treated with an anti-CD20 agent.